Related Experiment Video
Updated: Aug 24, 2026
An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
Published on: January 13, 2023
Photodynamic therapy of pterygium with verteporfin: a preliminary report
Maurizio Fossarello1, Enrico Peiretti, Ignazio Zucca
1Department of Surgical Sciences, Eye Clinic, University of Cagliari, I-09124 Cagliari, Italy. mfossarello@libero.it
Objective:
To assess the efficacy and safety of treating pterygia by photodynamic therapy (PDT) with verteporfin (Visudyne).
Materials And Methods:
Ten consecutive patients with primary, recurrent, or secondary pterygium, refusing excisional surgery, were treated with a 689-nm laser delivered directly onto the pterygium after verteporfin infusion. Postoperative outcome was followed clinically and photographically for a minimum of 3 months.
Results:
Successful photothrombosis of pterygium vascularization was obtained immediately after treatment in all cases. After 1 month, revascularization of pterygia was observed in 70% of cases, and treatment was repeated after a 3-month interval. Regression or stabilization of pterygia was manifested by a scarring reaction of the corneal apex with complete or partial disappearance of vascularity. No relevant side effects were observed in our series.
Conclusion:
PDT with verteporfin is a safe procedure to arrest the growth of pterygia. It is indicated for patients with a low- or medium-grade pterygium that refuse a surgical approach; however, multiple sessions may be required.
